First Trust Dorsey Wright Dynamic Focus 5 ETF
Limited financial coverage for FVC.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
This exchange-traded fund is constructed to largely replicate the financial performance, including both capital growth and income returns, of the Dorsey Wright Dynamic Focus Five Index. This target is aimed for prior to the deduction of the fund's own operating expenses and charges.
- IPO
- 2016
- HQ
- Wheaton, IL, US
Get TickerSpark's AI analysis on FVC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $122.74M
- Div Yield
- 1.27%
- 52W High
- $44.23
- 52W Low
- $33.81
- 50D MA
- $42.13
- 200D MA
- $39.58
- Beta
- 1.23
- RSI (14)
- 61
- Avg Volume
- 2.70K
No earnings-call transcripts are available for FVC yet.
- Free Float
- 0.0%
- Shares Outstanding
- 2.84M
- Float Shares
- 0
of shares held by institutions
52 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Prospera Financial Services Inc | 219.32K | ▼ 38.64K |
| Morgan Stanley | 207.93K | ▼ 11.91K |
| Wells Fargo & Company/Mn | 179.65K | ▼ 1.51K |
| Lpl Financial LLC | 146.06K | ▼ 81.28K |
| Bank Of America Corp | 125.80K | ▼ 2.63K |
| Ubs Group AG | 104.82K | ▼ 16.15K |
| Raymond James Financial Inc | 55.39K | ▼ 3.75K |
| Janney Montgomery Scott LLC | 32.98K | ▼ 400 |
| Global Retirement Partners, LLC | 30.66K | ▲ 30.66K |
| Geneos Wealth Management Inc. | 25.23K | ▼ 4.41K |
| Sun Financial Inc | 23.24K | ▼ 1 |
| Royal Bank Of Canada | 22.42K | ▼ 396 |
Our FVC coverage
Recent articles, reports, and earnings notes.
No research on FVC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FVC report →Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (
gurufocus.com · Aug 25
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
gurufocus.com · Aug 25
PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
businesswire.com · Dec 16
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
https://www.businesswire.com · May 20
Top ETF Stories of May 2022
zacks.com · May 31
5 ETFs to Tap Hedge Funds' First Inflow in Three Years
zacks.com · Dec 16
Hedge Fund Assets Hit Record in Q1: 5 ETFs to Tap
zacks.com · Apr 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.